» Articles » PMID: 21094951

Efficacy and Safety of Oral Versus Intravenous Ibuprofen in Very Low Birth Weight Preterm Infants with Patent Ductus Arteriosus

Overview
Journal J Pediatr
Specialty Pediatrics
Date 2010 Nov 25
PMID 21094951
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To compare oral ibuprofen with intravenous ibuprofen for closure of patent ductus arteriosus in very low birth weight (VLBW) preterm infants.

Study Design: In a prospective, randomized study, 102 VLBW preterm infants with patent ductus arteriosus received either intravenous or oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours. The success rate and evaluation of renal tolerance using cystatin-C were the major outcomes.

Results: Patent ductus arteriosus closure rate was significantly higher with oral ibuprofen (84.6% versus 62%) after the first course of the treatment (P = .011). The cystatin-C level increased significantly after treatment in the oral group (P = .001), but did not change with intravenous ibuprofen (P = .4).

Conclusions: Oral ibuprofen is more effective than intravenous ibuprofen for ductal closure in VLBW infants. The increase in the cystatin-C level with oral treatment suggests that patients with borderline renal function should be evaluated and followed closely.

Citing Articles

Use of NSAIDs and acetaminophen and risk of spontaneous intestinal perforations in premature infants: a systematic review and meta-analysis.

Hudson J, Shabbir W, Hayawi L, Chan M, Barrowman N, Sikora L Front Pediatr. 2024; 12:1450121.

PMID: 39649405 PMC: 11620902. DOI: 10.3389/fped.2024.1450121.


The impact of the route of administration on the efficacy and safety of the drug therapy for patent ductus arteriosus in premature infants: a systematic review and meta-analysis.

Luo H, He J, Xu X, Chen H, Shi J PeerJ. 2024; 12:e16591.

PMID: 38304184 PMC: 10832619. DOI: 10.7717/peerj.16591.


A Multi-Center Evaluation of the Pharmacokinetics and Safety of Intravenous Ibuprofen in Infants 1-6 Months of Age.

Glover C, Berkenbosch J, Taylor M, Patel N, Kaelin B, Gibson B Paediatr Drugs. 2023; 25(5):585-593.

PMID: 37294477 DOI: 10.1007/s40272-023-00576-9.


Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews.

Mitra S, de Boode W, Weisz D, Shah P Cochrane Database Syst Rev. 2023; 4:CD013588.

PMID: 37039501 PMC: 10091483. DOI: 10.1002/14651858.CD013588.pub2.


Comparison of Various Pharmacologic Agents in the Management of Hemodynamically Significant Patent Ductus Arteriosus in Preterm: A Network Meta-Analysis and Risk-Benefit Analysis.

Eursiriwan S, Okascharoen C, Vallibhakara S, Pattanaprateep O, Numthavaj P, Attia J Biomed Hub. 2022; 7(3):125-145.

PMID: 36465804 PMC: 9710462. DOI: 10.1159/000526318.